Literature DB >> 27699241

Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii.

Kamal El Bissati1, Aziz A Chentoufi2, Paulette A Krishack3, Ying Zhou1, Stuart Woods4, Jitender P Dubey5, Lo Vang6, Joseph Lykins1, Kate E Broderick7, Ernest Mui1, Yasuhiro Suzuki8, Qila Sa8, Stephanie Bi1, Nestor Cardona1, Shiv K Verma5, Laura Fraczek1, Catherine A Reardon3, John Sidney9, Jeff Alexander6, Alessandro Sette9, Tom Vedvick10, Chris Fox10, Jeffrey A Guderian10, Steven Reed10, Craig W Roberts4, Rima McLeod1.   

Abstract

We created and tested multi-epitope DNA or protein vaccines with TLR4 ligand emulsion adjuvant (gluco glucopyranosyl lipid adjuvant in a stable emulsion [GLA-SE]) for their ability to protect against Toxoplasma gondii in HLA transgenic mice. Our constructs each included 5 of our best down-selected CD8+ T cell-eliciting epitopes, a universal CD4+ helper T lymphocyte epitope (PADRE), and a secretory signal, all arranged for optimal MHC-I presentation. Their capacity to elicit immune and protective responses was studied using immunization of HLA-A*11:01 transgenic mice. These multi-epitope vaccines increased memory CD8+ T cells that produced IFN-γ and protected mice against parasite burden when challenged with T. gondii. Endocytosis of emulsion-trapped protein and cross presentation of the antigens must account for the immunogenicity of our adjuvanted protein. Thus, our work creates an adjuvanted platform assembly of peptides resulting in cross presentation of CD8+ T cell-eliciting epitopes in a vaccine that prevents toxoplasmosis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27699241      PMCID: PMC5033759          DOI: 10.1172/jci.insight.85955

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  45 in total

1.  Attachment and invasion of host cells by Toxoplasma gondii.

Authors:  L H Kasper; J R Mineo
Journal:  Parasitol Today       Date:  1994-05

2.  Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.

Authors:  Tze Guan Tan; Ernest Mui; Hua Cong; William H Witola; Alexandre Montpetit; Stephen P Muench; John Sidney; Jeff Alexander; Alessandro Sette; Michael E Grigg; Ajesh Maewal; Rima McLeod
Journal:  Vaccine       Date:  2010-03-26       Impact factor: 3.641

3.  Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected].

Authors:  Krystle A Lang Kuhs; Arielle A Ginsberg; Jian Yan; Roger W Wiseman; Amir S Khan; Niranjan Y Sardesai; David H O'Connor; David B Weiner
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

4.  Toxoplasma gondii: appearance of specific markers during the development of tissue cysts in vitro.

Authors:  A Lane; M Soete; J F Dubremetz; J E Smith
Journal:  Parasitol Res       Date:  1996       Impact factor: 2.289

5.  Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii.

Authors:  Hua Cong; Ernest J Mui; William H Witola; John Sidney; Jeff Alexander; Alessandro Sette; Ajesh Maewal; Rima McLeod
Journal:  Immunome Res       Date:  2010-12-03

Review 6.  Why prevent, diagnose and treat congenital toxoplasmosis?

Authors:  Rima McLeod; Francois Kieffer; Mari Sautter; Tiffany Hosten; Herve Pelloux
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-03       Impact factor: 2.743

7.  HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivo.

Authors:  Kar Muthumani; Megan C Wise; Kate E Broderick; Natalie Hutnick; Jonathan Goodman; Seleeke Flingai; Jian Yan; Chaoran B Bian; Janess Mendoza; Colleen Tingey; Christine Wilson; Krzysztof Wojtak; Niranjan Y Sardesai; David B Weiner
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

8.  From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.

Authors:  Rhea N Coler; Malcolm S Duthie; Kimberly A Hofmeyer; Jeffery Guderian; Lakshmi Jayashankar; Julie Vergara; Tom Rolf; Ayesha Misquith; John D Laurance; Vanitha S Raman; H Remy Bailor; Natasha Dubois Cauwelaert; Steven J Reed; Aarthy Vallur; Michelle Favila; Mark T Orr; Jill Ashman; Prakash Ghosh; Dinesh Mondal; Steven G Reed
Journal:  Clin Transl Immunology       Date:  2015-04-10

9.  Location of the CD8 T cell epitope within the antigenic precursor determines immunogenicity and protection against the Toxoplasma gondii parasite.

Authors:  Virginie Feliu; Virginie Vasseur; Harshita S Grover; H Hamlet Chu; Mark J Brown; Jeremy Wang; Jon P Boyle; Ellen A Robey; Nilabh Shastri; Nicolas Blanchard
Journal:  PLoS Pathog       Date:  2013-06-20       Impact factor: 6.823

10.  Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine.

Authors:  Margaret E McCoy; Hannah E Golden; Tais Apf Doll; Yongkun Yang; Stephen A Kaba; Xiaoyan Zou; Vincent R Gerbasi; Peter Burkhard; David E Lanar
Journal:  Malar J       Date:  2013-04-22       Impact factor: 2.979

View more
  18 in total

Review 1.  Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development.

Authors:  Ki-Back Chu; Fu-Shi Quan
Journal:  Vaccines (Basel)       Date:  2021-04-21

2.  Point-of-care testing for Toxoplasma gondii IgG/IgM using Toxoplasma ICT IgG-IgM test with sera from the United States and implications for developing countries.

Authors:  Ian J Begeman; Joseph Lykins; Ying Zhou; Bo Shiun Lai; Pauline Levigne; Kamal El Bissati; Kenneth Boyer; Shawn Withers; Fatima Clouser; A Gwendolyn Noble; Peter Rabiah; Charles N Swisher; Peter T Heydemann; Despina G Contopoulos-Ioannidis; Jose G Montoya; Yvonne Maldonado; Raymund Ramirez; Cindy Press; Eileen Stillwaggon; François Peyron; Rima McLeod
Journal:  PLoS Negl Trop Dis       Date:  2017-06-26

3.  A Poly(Lactic-co-Glycolic) Acid Nanovaccine Based on Chimeric Peptides from Different Leishmania infantum Proteins Induces Dendritic Cells Maturation and Promotes Peptide-Specific IFNγ-Producing CD8+ T Cells Essential for the Protection against Experimental Visceral Leishmaniasis.

Authors:  Evita Athanasiou; Maria Agallou; Spyros Tastsoglou; Olga Kammona; Artemis Hatzigeorgiou; Costas Kiparissides; Evdokia Karagouni
Journal:  Front Immunol       Date:  2017-06-13       Impact factor: 7.561

4.  A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Leishmania donovani Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Leishmania amazonesis Infection.

Authors:  Marcus Vinícius Alves-Silva; Dirlei Nico; Alexandre Morrot; Marcos Palatnik; Clarisa B Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2017-02-23       Impact factor: 7.561

5.  A flexible MHC class I multimer loading system for large-scale detection of antigen-specific T cells.

Authors:  Jolien J Luimstra; Malgorzata A Garstka; Marthe C J Roex; Anke Redeker; George M C Janssen; Peter A van Veelen; Ramon Arens; J H Frederik Falkenburg; Jacques Neefjes; Huib Ovaa
Journal:  J Exp Med       Date:  2018-04-17       Impact factor: 14.307

6.  Protein nanovaccine confers robust immunity against Toxoplasma.

Authors:  Kamal El Bissati; Ying Zhou; Sara Maria Paulillo; Senthil Kumar Raman; Christopher P Karch; Craig W Roberts; David E Lanar; Steve Reed; Chris Fox; Darrick Carter; Jeff Alexander; Alessandro Sette; John Sidney; Hernan Lorenzi; Ian J Begeman; Peter Burkhard; Rima McLeod
Journal:  NPJ Vaccines       Date:  2017-09-05       Impact factor: 7.344

Review 7.  Global initiative for congenital toxoplasmosis: an observational and international comparative clinical analysis.

Authors:  Kamal El Bissati; Pauline Levigne; Joseph Lykins; El Bachir Adlaoui; Amina Barkat; Amina Berraho; Majda Laboudi; Bouchra El Mansouri; Azeddine Ibrahimi; Mohamed Rhajaoui; Fred Quinn; Manoradhan Murugesan; Fouad Seghrouchni; Jorge Enrique Gómez-Marín; François Peyron; Rima McLeod
Journal:  Emerg Microbes Infect       Date:  2018-09-27       Impact factor: 7.163

8.  Editorial: Innovative Therapeutic and Immunomodulatory Strategies for Protozoan Infections.

Authors:  Jorge Enrique Gómez Marín; Kamal El Bissati
Journal:  Front Cell Infect Microbiol       Date:  2019-08-09       Impact factor: 5.293

9.  Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer.

Authors:  Huân M Ngô; Ying Zhou; Hernan Lorenzi; Kai Wang; Taek-Kyun Kim; Yong Zhou; Kamal El Bissati; Ernest Mui; Laura Fraczek; Seesandra V Rajagopala; Craig W Roberts; Fiona L Henriquez; Alexandre Montpetit; Jenefer M Blackwell; Sarra E Jamieson; Kelsey Wheeler; Ian J Begeman; Carlos Naranjo-Galvis; Ney Alliey-Rodriguez; Roderick G Davis; Liliana Soroceanu; Charles Cobbs; Dennis A Steindler; Kenneth Boyer; A Gwendolyn Noble; Charles N Swisher; Peter T Heydemann; Peter Rabiah; Shawn Withers; Patricia Soteropoulos; Leroy Hood; Rima McLeod
Journal:  Sci Rep       Date:  2017-09-13       Impact factor: 4.379

10.  Recruitment of Intratumoral CD103+ Dendritic Cells by a CXCR4 Antagonist-Armed Virotherapy Enhances Antitumor Immunity.

Authors:  Anna Mistarz; Marcin P Komorowski; Matthew A Graczyk; Margaret Gil; Aimin Jiang; Mateusz Opyrchal; Hanna Rokita; Kunle O Odunsi; Danuta Kozbor
Journal:  Mol Ther Oncolytics       Date:  2019-07-03       Impact factor: 6.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.